THE IMPROVEMENT IN CLAUDICATION DISTANCE FOLLOWING 3 MONTH TREATMENT WITH CILOSTAZOL IN PATIENTS WITH MILD TO MODERATE PERIPHERAL ARTERIAL DISEASE

ABSTRACT
Objective: To study the effects of Cilostazol in patients with mild to moderate Peripheral Arterial Disease (PAD) with
regards to improvement in the Claudication Distance (CD)
Methodology: This hospital based interventionist study was a prospective, open labeled clinical trial. After the baseline
data collection Cilostazol was given to the group A, while the group B did not receive Cilostazol. The effect of
intervention was noted at the timed study points at 4 weeks, 6 weeks and 12 weeks. The anti-platelets were used in
the group B as a control.
Results: The CD improvement at the end of the study in the cilostazol treated group was marked compared with the
control group. The study participants included 65 males in group A and 74 males in group B, while females made up
of 35 number in group A and 26 in group B. the overall total improvement in CD with a P value of 0.0001 was noted in
the cilostazol treated group. The results showed marked improvement in the male, diabetic and hypertensive subsets
of the study, moderate improvement in the smoker subset and a mild less marked response in the obese category.
Conclusion: Cilostazol produces significantly improvement in the claudication distance. Its use in the indicated population
group should be encouraged to improve the management and the prevent the complications of PAD especially
in the diabetic and hypertensive patients with this disease.
Keywords: Atherosclerosis, Claudication distance, Peripheral arterial disease, Cilostazol